Latest Biosimilars in Asian Scenario

Formal legislation to ensure rigorous regulatory and testing standards for biosimilars (in place of the less regulated ‘copy biologics’) began to appear in 2008–2009, with Australia, Malaysia, South Korea, and Japan among the first countries in the region to implement these strict approval requirements. More recently, India (2012) and China (2015) have finalized their own national guidelines. There are currently more biosimilar products in development across the Asia-Pacific region than anywhere else in the world, leading to a wealth of opportunities for investors and patients to take part in biosimilar clinical trials. This track covers topics such as: 

  • Prospects of Biosimilars in Asian market
  • Approved Biosimilars in Asia-Pacific Region
  • Regulatory guidelines in the Asia-Pacific region
  • Market strategy, analysis and Risk Management for Biosimilars in Asia market

Related Conference of Latest Biosimilars in Asian Scenario

June 06-07, 2018

International Conference on Pharmaceutical Research and Development

Philadelphia, Pennsylvania, USA
June 08-09, 2018

8th International Conference and Exhibition on GMP, GCP & Quality Control

Philadelphia, Pennsylvania, USA
June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan

3rd International Conference on Generics Drugs and Biosimilars

November 15-17, 2018 | Frankfurt, Germany
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
August 15-17, 2018

8th World Congress Spectroscopy and Analytical Techniques

Stockholm, Sweden
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Latest Biosimilars in Asian Scenario Conference Speakers

Recommended Sessions

Related Journals

Are you interested in